The Rational Design of Specific Peptide Inhibitor against p38α MAPK at Allosteric-Site: A Therapeutic Modality for HNSCC

Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase

(2012) Kamaldeep Gill et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Quantification of p38αMAP kinase: A prognostic marker in HNSCC with respect to radiation therapy

(2011) Kamaldeep Gill et al.   CLINICA CHIMICA ACTA

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

(2011) F. Sievers et al.   Molecular Systems Biology

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796

(2010) Justin Dietrich et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

(2010) Tianjun Zhou et al.   Chemical Biology & Drug Design

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

(2009) Fabio Zuccotto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selectively Nonselective Kinase Inhibition: Striking the Right Balance

(2009) Richard Morphy   JOURNAL OF MEDICINAL CHEMISTRY

High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38α

(2009) Jeffrey R. Simard et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY